Korea Research Institute of Bioscience and Biotechnology

The Catholic University of Korea Industry-academic Cooperation Foundation

Industry-academic Cooperation Foundation, the Catholic University of Korea

Catholic University Industry Academic Cooperation Foundation

Bifido Co., Ltd.

The Catholic University of Korea

Mi La Cho

Jun Geol Ryu

Young Woo Park

Sung Hwan Park

Jung Jae Yu

Mi Kyung Park

Ho Youn Kim

Ki Won Jo

Joo Yeon Jhun

Eun Jung Song

Seon Yeong Lee

Jin Sil Park

Jae Kyeong Byun

Yun Ju Woo

Sun-Ha Yoon

Srok Ho Yoo

Hye Jwa Oh

Jong-Ho Lee

Eun Kyung Kim

Eun Kyung Lee

Sang Jun Park

Ji Won Kim

Ji Hyun Park

Min-Jung Park

Yun Ju Jeong

Jung Hee Kim

Dong Jin Kim

Geun Eog Ji

Min Ji Seo

Kyu Won Cho

Ji Hyeon Ju

Seung Ki Kwok

Seung Kew Yoon

Jong Young Choi

Chul Woo Yang

Min Jung Park

Jung-Yeon Lim

Eun Jung Lee

Jae Kyung Kim

Jung Eun Choi

Jin Mi Oh

Sun Jung Cho

Eun Byul Lee

Joo Ha Lee

Sun Woo Lim

Won Hee Hur

Hyun-Sil Park

Seok-Goo Cho

Jae Yoon Ryu

Hyon Ha Lee

Su Young Yang

Disclosed are a novelRAPO (Accession No.: KCTC 13773BP) and a composition for alleviating, treating or preventing rheumatoid arthritis containingRAPO (Accession No.: KCTC 13773BP) selected herein.

RAPO strain for alleviating, treating or preventing rheumatoid arthritis and composition containing the same

The present invention relates to a cell therapy composition for preventing or treating immune disease comprising mesenchymal stem cells and immunoregulatory T-cells as an active ingredient. By infusing mesenchymal stem cells and immunoregulatory T-cells, which are the cellular therapeutic agent of the present invention, into bone marrow transplant animals, rejection to the host is suppressed after the engraftment of the transplanted bone-marrow to thus obtain the effect of reducing graft-versus-host disease and immune disease. Moreover, the effect of such GVHD reduction is much greater than the one obtained when only mesenchymal stem cells are infused. Accordingly, the cell therapy composition of the present invention having the above-mentioned effects can be useful in the prevention or treatment of immune disease.

Cell therapy composition for preventing or treating immune disease comprising mesenchymal stem cells and immunoregulatory t-cells as active ingredient

The present invention relates to a pharmaceutical composition for preventing or treating hepatitis C virus (HCV) infectious disease. More particularly, the present invention relates to a pharmaceutical composition for preventing or treating HCV infectious disease or an antiviral composition for HCV, containing at least one selected from the group consisting of: GRIM19 protein or a fragment thereof; and a gene encoding the protein or a fragment of the protein.

Methods for treating hepatitis C virus infectious disease

Provided is a composition for alleviating nephrotoxicity caused by an immunosuppressive drug, including metformin, and a composition for preventing or treating an immune disease, including the same. Further, the composition provided can be useful in improving a treatment effect on diseases requiring immunosuppression by effectively alleviating a decline in renal function caused due to side effects of conventional immunosuppressive drugs, and can also be useful in preventing or treating organ transplant rejection, autoimmune diseases, inflammatory diseases and the like since various methods of co-administering a conventional immunosuppressive drug and metformin are suggested to reduce nephrotoxic side effects of conventional immunosuppressive drugs and maximize immunosuppressive or immunomodulatory effects.

Composition for alleviating nephrotoxicity caused by immunosuppressive drug, comprising metformin, and composition for preventing or treating immune disease, comprising the same

The present invention relates to TNFR2-IL21R fusion protein acting as a double-antagonist to TNF-alpha (&#x3b1;) and IL-21. The composition containing the double antagonist to TNF-&#x3b1; and Il-21 (TNFR2-IL21R fusion protein), known as major causes of autoimmune rheumatoid arthritis, one of autoimmune diseases, can reduce the secretion of inflammatory cytokine, increase the secretion of anti-inflammatory cytokine, and suppress the differentiation of osteoclasts better than single proteins such as TNFR2-Fc and IL21R-Fc. The TNFR2-IL21R fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells. Therefore, the TNFR2-IL21R fusion protein of the present invention can be effectively used as an active ingredient for the composition for the prevention and treatment of autoimmune disease.

Dual antagonist for TNF-&#x3b1; and IL-21 for preventing and treating autoimmune diseases

The present invention relates to TNFR2-TWEAKR fusion protein, more precisely to TNFR2-TWEAKR fusion protein acting as a double-antagonist to TNF-&#x3b1; and TWEAK, known as major causes of autoimmune arthritis which is one of autoimmune diseases. When the composition comprising TNFR2-TWEAKR fusion protein was treated to Th17 cells, the secretion of the inflammatory cytokine IL-17 was reduced but the secretion of the anti-inflammatory cytokine IL-10 generated in Treg cells was increased. Such effect of TNFR2-TWEAKR fusion protein was far greater than that of a single protein such as TNFR2-Fc or TWEAK-Fc. The TNFR2-TWEAKR fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells. Therefore, the TNFR2-TWEAKR fusion protein of the present invention can be effectively used as an active ingredient for the composition for the prevention and treatment of autoimmune disease.

TNF-A and TWEAK dual antagonist for the prophylaxis and treatment of autoimmune diseases

Growing community of inventors

Seoul, South Korea

Mi La Cho